Analysis of the effects of ha-330 hemo adsorption column application on mortality and morbidity of adult patients with sepsis in general intensive care unit

Sepsis is a leading cause of mortality and morbidity in critical care units. The objective of this study is to evaluate if using the HA-330 Sepsis Adsorption Column in the intensive care unit reduces mortality and morbidity in patients with sepsis. This study was designed as a retrospective study evaluating demographic and laboratory parameters in the General Intensive Care Unit. The study involved 200 sepsis patients who were followed in the critical care unit between June 2019- December 2020 and were treated with the HA-330 Sepsis Adsorption Column. The length of hemoperfusion in patients who died was statistically significantly longer than in patients who recovered. The mean lactate and the hemoperfusion time/day value had a weak but significant negative correlation. In the recovery and death observations, the improvements in repeated C-reactive protein and Procalcitonin measurements were statistically significantly different. The differences in repeated pH and lactate measurements in the recovery and mortality observations were statistically identical, according to the observations. Sepsis-related deaths are a severe issue in critical care units. HA-330 Sepsis Adsorption Column, it can be thought that it can be an inexpensive, useful, and effective method that can be used in the prognosis of the patients. In antibiotic-resistant sepsis, hemoperfusion may be recommended.

PDF

___

1. Singer M, Deutschman CS, Seymour CW, et al. The third ınternational consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10.

2. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-77.

3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS International sepsis definitions conference. Intensive care med. 2003;29:530-8.

4. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969-87.

5. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.

6. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:4-11.

7. Gullo A, Bianco N, Berlot G. Management of severe sepsis and septic shock: challenges and recommendations. Crit Care Clin. 2006;22:489-501.

8. Marshall JC, Reinhart K; International Sepsis Forum. Biomarkers of sepsis. Crit Care Med. 2009;37:2290-98.

9. Kaplan, J.M. and H.R. Wong, Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12:165-73.

10. Standage, S.W. and H.R. Wong, Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9:71-9.

11. Faraj, M. and N. Salem, C-reactive protein. Intech Journal. 2012:89-100.

12. Meisner, M., Pathobiochemistry and clinical use of procalcitonin.Clin Chim Acta. 2002;323:17-29.

13. Wiedermann FJ, Kaneider N, E gger P, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30:1112-7.

14. Kumar S, Rizvi M. Serum tumor necrosis factor alpha and C-reactive protein in pediatric patients with sepsis and its correlation with microbiologic findings. Indian J Pathol Microbiol. 2010;53:494-7.

15. Esmaeili Vardanjani A, Ronco C, Rafiei H, et al. Early hemoperfusion for cytokine removal may contribute to prevention of ıntubation in patients ınfected with COVID-19. Blood Purif. 2021;50:257-60.

16. Bullock B. Benham MD. Bacterial sepsis, in StatPearls. 2021, StatPearls Publishing Copyright © 2019.

17. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3) [published correction appears in JAMA. JAMA. 2016;315:762-74.

18. Sprung CL, Sakr Y, Vincent JL, et al. An evaluation of systemic inflammatory response syndrome signs in the sepsis occurrence ın acutely Ill patients (SOAP) study. Intensive Care Med. 2006;32:421-7.

19. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372:1301-11.

20. Guirgis FW, Puskarich MA, Smotherman C, et al. Development of a simple sequential organ failure assessment score for risk assessment of emergency department patients with sepsis. J Intensive Care Med. 2020;35:270-8.

21. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372:1629- 38.

22. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372:1629- 38.

23. Tang Y, Zhang L, Fu P, et al. Hemoperfusion plus continuous veno-venous hemofiltration in a pregnant woman with severe acute pancreatitis: a case report. Int Urol Nephrol. 2012;44:987-90.

24. Chu L, Li G, Yu Y, et al. Clinical effects of hemoperfusion combined with pulse high-volume hemofiltration on septic shock. Medicine (Baltimore). 2020;99:e19058.

25. Pepys, M.B. and G.M. Hirschfield, C-reactive protein: a critical update. J Clin Invest, 2003;111:1805-12.

26. Nelson GE, Mave V, Gupta A. Biomarkers for sepsis: a review with special attention to India. Biomed Res Int. 2014;2014:264351.

27. Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123:2043- 49.

28. Simon L, Gauvin F, Amre DK, et al., Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206-17.

29. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819-27.

30. Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006;12:315-21.

31. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:775-87.

32. ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, et al. Goaldirected resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496-506.

33. ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683- 93.

34. Casserly B, Phillips GS, Schorr C, et al. Lactate measurements in sepsisinduced tissue hypoperfusion: results from the surviving sepsis campaign database. Crit Care Med. 2015;43:567-73.

35. Khwannimit B, Bhurayanontachai R, Vattanavanit V. Comparison of the performance of SOFA, qSOFA and SIRS for predicting mortality and organ failure among sepsis patients admitted to the intensive care unit in a middleincome country. J Crit Care. 2018;44:156-60.

36. Freund Y, Lemachatti N, Krastinova E, et al. Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. JAMA. 2017;317:301-8.